Biotech Stocks SYRE, BFLY Surge on Clinical Data, Regulatory Wins

Biotech stocks Syros Pharmaceuticals (SYRE) and Butterfly Network (BFLY) lead significant year-to-date gains, surging 400% and 300% respectively as of June 20, 2026. Regenxbio (RGNX), Arcturus Therapeutics (ARCT), and Editas Medicine (EDIT) each posted 100% increases, driven by positive clinical trial results and regulatory advancements. Syros Pharmaceuticals' 400% YTD rise follows favorable Phase 1 data for its selective CDK7 inhibitor SY-5601, targeting HR+/HER2- breast cancer. Butterfly Network's 300% increase stems from its Butterfly iQ handheld ultrasound device and recent FDA 510(k) clearance for its AI-enabled Auto B-line Counter. Regenxbio (RGNX) gained 100% on positive interim Phase 2 data for its wet AMD gene therapy. Arcturus Therapeutics (ARCT) climbed 100% after positive Phase 3 results for its COVID-19 mRNA vaccine, while Editas Medicine (EDIT) achieved a 100% increase with initial positive data for its sickle cell gene editing therapy.